Tom 15, Nr 2 (2022)
Artykuł przeglądowy
Opublikowany online: 2022-07-12
Wyświetlenia strony
2389
Wyświetlenia/pobrania artykułu
1047
DOAC — nie u każdego i czasem w innych dawkach
Journal of Transfusion Medicine 2022;15(2):154-158.
Streszczenie
Doustne bezpośrednie inhibitory krzepnięcia (DOAC) stosuje się w Europie już od ponad 10 lat. Jedną z ich istotnych zalet jest stosowanie w profilaktyce i leczeniu stałych dawek leków. Niekiedy preferuje się jednak starsze leki przeciwzakrzepowe (antywitaminy K, heparyny) lub w pewnych sytuacjach klinicznych modyfikuje się standardowe, zalecane dawki DOAC.
Słowa kluczowe: bezpośrednie doustne inhibitory krzepnięciamigotanie przedsionkówzespół antyfosfolipidowychoroba nerekżylna choroba zakrzepowo-zatorowa
Referencje
- Jame S, Barnes G. Stroke and thromboembolism prevention in atrial fibrillation. Heart. 2020; 106(1): 10–17.
- Ortel TL, Neumann I, Ageno W, et al. American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism. Blood Adv. 2020; 4(19): 4693–4738.
- Bayer V, Kotalczyk A, Kea B, et al. Global Oral Anticoagulation Use Varies by Region in Patients With Recent Diagnosis of Atrial Fibrillation: The GLORIA-AF Phase III Registry. J Am Heart Assoc. 2022; 11(6): e023907.
- Woller SC, Stevens SM, Kaplan D, et al. Apixaban compared with warfarin to prevent thrombosis in thrombotic antiphospholipid syndrome: a randomized trial. Blood Adv. 2022; 6(6): 1661–1670.
- Pengo V, Denas G, Zoppellaro G, et al. Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome. Blood. 2018; 132(13): 1365–1371.
- Martinelli I, Abbattista M, Bucciarelli P, et al. Recurrent thrombosis in patients with antiphospholipid antibodies treated with vitamin K antagonists or rivaroxaban. Haematologica. 2018; 103(7): e315–e317.
- Ordi-Ros J, Sáez-Comet L, Pérez-Conesa M, et al. Rivaroxaban Versus Vitamin K Antagonist in Antiphospholipid Syndrome: A Randomized Noninferiority Trial. Ann Intern Med. 2019; 171(10): 685–694.
- Pastori D, Menichelli D, Cammisotto V, et al. Use of Direct Oral Anticoagulants in Patients With Antiphospholipid Syndrome: A Systematic Review and Comparison of the International Guidelines. Front Cardiovasc Med. 2021; 8: 715878.
- Chan KE, Edelman ER, Wenger JB, et al. Dabigatran and rivaroxaban use in atrial fibrillation patients on hemodialysis. Circulation. 2015; 131(11): 972–979.
- Wang X, Tirucherai G, Marbury TC, et al. Pharmacokinetics, pharmacodynamics, and safety of apixaban in subjects with end-stage renal disease on hemodialysis. J Clin Pharmacol. 2016; 56(5): 628–636.
- Wadsworth D, Sullivan E, Jacky T, et al. A review of indications and comorbidities in which warfarin may be the preferred oral anticoagulant. J Clin Pharm Ther. 2021; 46(3): 560–570.
- Cheung CYS, Parikh J, Farrell A, et al. Direct Oral Anticoagulant Use in Chronic Kidney Disease and Dialysis Patients With Venous Thromboembolism: A Systematic Review of Thrombosis and Bleeding Outcomes. Ann Pharmacother. 2021; 55(6): 711–722.
- Nishimura RA, Otto CM, Bonow RO, et al. 2017 AHA/ACC Focused Update of the 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2017; 135(25): e1159–e1195.
- Eikelboom JW, Connolly SJ, Brueckmann M, et al. RE-ALIGN Investigators. Dabigatran versus warfarin in patients with mechanical heart valves. N Engl J Med. 2013; 369(13): 1206–1214.
- Connolly S, Ezekowitz M, Yusuf S, et al. Dabigatran versus Warfarin in Patients with Atrial Fibrillation. N Engl J Med . 2009; 361(12): 1139–1151.
- Connolly S, Eikelboom J, Joyner C, et al. Apixaban in Patients with Atrial Fibrillation. N Engl J Med. 2011; 364(9): 806–817.
- Camm A, Cools F, Virdone S, et al. Mortality in Patients With Atrial Fibrillation Receiving Nonrecommended Doses of Direct Oral Anticoagulants. J Am Coll Cardiol. 2020; 76(12): 1425–1436.
- Carlin S, Eikelboom JW. Direct oral anticoagulant dose selection: Challenging cases. J Thromb Haemost. 2021; 19(11): 2680–2686.
- Bingzheng X, Jingnan R, Ligang B, et al. The effects of anticoagulant therapy re-initiation after gastrointesitinal bleeding: a systematic review and meta-analysis. J Clin Pharm Ther. 2021; 46(6): 1509–1518.
- Xu Y, Siegal DM. Anticoagulant-associated gastrointestinal bleeding: Framework for decisions about whether, when and how to resume anticoagulants. J Thromb Haemost. 2021; 19(10): 2383–2393.
- Agnelli G, Buller HR, Cohen A, et al. AMPLIFY-EXT Investigators. Apixaban for extended treatment of venous thromboembolism. N Engl J Med. 2013; 368(8): 699–708.
- Weitz J, Lensing A, Prins M, et al. Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism. N Engl J Med . 2017; 376(13): 1211–1222.
